Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers: Cell-Free Nucleic Acids, Proteins and Rare Circulating Cells

Eric Kaldjian's Biography



Eric Kaldjian, Chief Medical Officer, RareCyte

Eric is Chief Medical Officer of RareCyte, directing scientific and medical applications of its rare cell detection technology. Before joining RareCyte he was Medical Director for Companion Diagnostics at Ventana Medical Systems/Roche. His pharmaceutical experience at Hoffmann-La Roche and at Parke-Davis/Pfizer encompassed discovery research through full clinical development positions with a focus on translational medicine. He was Chief Scientific Officer at Transgenomic and directed clinical genomics programs at Gene Logic. He received his anatomic pathology training at the University of Michigan and was a hematopathology/immunology fellow at the National Cancer Institute. He is an associate member of the BioInterfaces Institute at the University of Michigan.

Eric Kaldjian Image

Longitudinal Whole Exome Investigation of Mutational Heterogeneity in Single CTCs in a Patient with Triple-Negative Breast Cancer

Tuesday, 21 March 2017 at 09:00

Add to Calendar ▼2017-03-21 09:00:002017-03-21 10:00:00Europe/LondonLongitudinal Whole Exome Investigation of Mutational Heterogeneity in Single CTCs in a Patient with Triple-Negative Breast CancerSELECTBIOenquiries@selectbiosciences.com

We performed whole exome sequencing of single CTCs from a patient with metastatic triple-negative breast cancer to investigate the evolution of genetic heterogeneity during therapy.  CTCs were identified using the AccuCyte-CyteFinder system (RareCyte) and individually retrieved from microscope slides using the integrated CytePicker function.  Single cell whole genome amplication was performed followed by whole exome sequencing.   Computational biology tools were employed to analyze genomic DNA sequence from multiple CTCs, white blood cells and ctDNA from various time points. Genomic sequence alterations were observed to evolve over the course of therapy in individual CTCs.  These alterations appear to be generally consistent within CTC at a given time point.  The number of predicted deleterious and cancer driver mutations per CTC were observed to increase in frequency after effective treatments, suggesting that the number of such alterations may be associated with resistance to therapy.


Add to Calendar ▼2017-03-20 00:00:002017-03-21 00:00:00Europe/LondonCirculating Biomarkers: Cell-Free Nucleic Acids, Proteins and Rare Circulating CellsSELECTBIOenquiries@selectbiosciences.com